Who makes Latanoprost bunod 0.024%?

Latanoprost bunod 0.024% is developed by Icahn School of Medicine at Mount Sinai.

What development phase is Latanoprost bunod 0.024% in?

Latanoprost bunod 0.024% is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Latanoprost bunod 0.024%

Icahn School of Medicine at Mount Sinai · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Latanoprost bunod 0.024%
Also known as	Vyzulta, LTB
Sponsor	Icahn School of Medicine at Mount Sinai
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Nailfold Capillary Blood Flow With Latanoprost Bunod (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Latanoprost bunod 0.024% CI brief — competitive landscape report
Latanoprost bunod 0.024% updates RSS · CI watch RSS
Icahn School of Medicine at Mount Sinai portfolio CI